Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer

Abstract

The goal of the current study was to determine the efficacy of oral docetaxel in combination with cyclosporine in the treatment of canine epithelial cancer. Requirements for eligibility were histological confirmation of epithelial neoplasia, measurable disease, no chemotherapy treatment within 2 weeks, and a life expectancy of ≥ 3 months. Fifty-one dogs were enrolled. All dogs received 1.625 mg kg(-1) of docetaxel with 5 mg kg(-1) of cyclosporine (DT/CSA) by gavage. Ten dogs had progressive disease at 2 weeks, one dog died, and one dog was withdrawn from the study. Thirty-nine dogs were given a second dose of DT/CSA, three each receiving a third or fourth dose. Eight dogs had a dose reduction (1.5 mg kg(-1)) and six dogs had treatment delays primarily for gastrointestinal toxicity. The overall response rate was 16.7% (8/48 had a partial response there were no complete responses). The highest response rate was seen in dogs with oral squamous cell carcinoma (50%; 6/12).

Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection

“…Of particular note, PCA cell lines did not appear to be more sensitive to docetaxel compared to iUC cell lines. These cell culture findings are not incongruent with recently described activity of docetaxel in dogs with epithelial malignancies [ 46 ]. In this phase II study, 51 dogs were treated with docetaxel with an objective response rate of 16.7% (8/48 partial responses), however only ~ 20% of the evaluated patient population had uroepithelial carcinomas (8 bladder and 2 prostate) and clinical response rates were not different between these 2 limited subpopulations.…”

<i>In Vitro</i> Characterization of Docetaxel as a Radiosensitizer in Canine and Feline Cancer Cell Lines

“…A phase II study to determine the efficacy of oral docetaxel in the management of canine epithelial tumors has been completed. In this study canine oral squamous cell carcinoma was found to be responsive to oral docetaxel [36]. Furthermore a phase II study to determine the efficacy of oral docetaxel in the management of feline epithelial tumors targeting oral squamous cell carcinoma is currently ongoing.…”